Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex

Blood

Volumn 118, Issue 1, 2011, Pages 60-68

  Verstraete, Kenneth ^a   Vandriessche, Gonzalez ^a   Januar, Mariska ^a   Elegheert, Jonathan ^a   Shkumatov, Alexander V ^b   Desfosses, Ambroise ^c   Van Craenenbroeck, Kathleen ^a   Svergun, Dmitri I ^b   Gutsche, Irina ^c   Vergauwen, Bjorn ^a   Savvides, Savvas N ^a  

^a GHENT UNIVERSITY   (Belgium)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; EPITOPE; FLT3 LIGAND;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DIMERIZATION; ENTROPY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 79960132110     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-329532     Document Type: Article

References (56)

1. Metcalf D. Hematopoietic cytokines. Blood. 2008;111(2):485-491.
2. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650-665. (Pubitemid 37328820)
3. Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells. 2006;24(5):1174-1184. (Pubitemid 44464685)
4. Kikushige Y, Yoshimoto G, Miyamoto T, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol. 2008;180(11):7358-7367.
5. Liu K, Victora GD, Schwickert TA, et al. In vivo analysis of dendritic cell development and homeostasis. Science. 2009;324(5925):392-397.
6. Onai N, Obata-Onai A, Schmid MA, Ohteki T, Jarrossay D, Manz MG. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol. 2007;8(11):1207-1216. (Pubitemid 350011759)
7. Waskow C, Liu K, Darrasse-Jeze G, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9(6):676-683. (Pubitemid 351712638)
8. Eidenschenk C, Crozat K, Krebs P, et al. Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells. Proc Natl Acad Sci U S A. 2010;107(21):9759-9764.
9. Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther. 2002;1(5):486-489.
10. Wu L, Liu YJ. Development of dendritic-cell lineages. Immunity. 2007;26(6):741-750. (Pubitemid 46908964)
11. Schmid MA, Kingston D, Boddupalli S, Manz MG. Instructive cytokine signals in dendritic cell lineage commitment. Immunol Rev. 2010;234(1):32-44.
12. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. 2010;234(1):45-54.
13. Grassot J, Gouy M, Perriere G, Mouchiroud G. Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains. Mol Biol Evol. 2006;23(6):1232-1241. (Pubitemid 43781597)
14. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-1134.
15. Sanz M, Burnett A, Lo-Coco F, Lowenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol. 2009;21(6):594-600.
16. Dehlin M, Bokarewa M, Rottapel R, et al. Intraarticular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS ONE. 2008;3(11):e3633.
17. Fröhling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6):501-513. (Pubitemid 350199072)
18. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21(16):2555-2563. (Pubitemid 34438108)
19. Reindl C, Bagrintseva K, Vempati S, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006;107(9):3700-3707.
20. Eklund EA. Genomic analysis of acute myeloid leukemia: potential for new prognostic indicators. Curr Opin Hematol. 2010;17(2):75-78.
21. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089-5102.
22. Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13(2):169-178. (Pubitemid 38183264)
23. Chen X, Liu H, Focia PJ, Shim AH, He X. Structure of macrophage colony stimulating factor bound to FMS: diverse signaling assemblies of class III receptor tyrosine kinases. Proc Natl Acad Sci U S A. 2008;105(47):18267-18272.
24. Leppänen VM, Prota AE, Jeltsch M, et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci U S A. 2010;107(6):2425-2430.
25. Liu H, Chen X, Focia PJ, He X. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J. 2007;26(3):891-901.
26. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol. 2007;14(3):249-250. (Pubitemid 46355572)
27. Shim AH, Liu H, Focia PJ, Chen X, Lin PC, He X. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci U S A. 2010;107(25):11307-11312.
28. Yang Y, Xie P, Opatowsky Y, Schlessinger J. Direct contacts between extracellular membraneproximal domains are required for VEGF receptor activation and cell signaling. Proc Natl Acad Sci U S A. 2010;107(5):1906-1911.
29. Yang Y, Yuzawa S, Schlessinger J. Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc Natl Acad Sci U S A. 2008;105(22):7681- 7686. (Pubitemid 351872698)
30. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell. 2007;130(2):323-334. (Pubitemid 47081138)
31. Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene. 1993;8(4):815-822. (Pubitemid 23087411)
32. Maroc N, Rottapel R, Rosnet O, et al. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene. 1993;8(4):909-918. (Pubitemid 23087422)
33. Lavagna C, Marchetto S, Birnbaum D, Rosnet O. Identification and characterization of a functional murine FLT3 isoform produced by exon skipping. J Biol Chem. 1995;270(7):3165-3171.
34. Broudy VC, Lin NL, Sabath DF. The fifth immunoglobulin-like domain of the Kit receptor is required for proteolytic cleavage from the cell surface. Cytokine. 2001;15(4):188-195. (Pubitemid 34587644)
35. Reeves PJ, Callewaert N, Contreras R, Khorana HG. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci U S A. 2002;99(21):13419-13424. (Pubitemid 35215396)
36. Verstraete K, Remmerie B, Elegheert J, et al. Inducible production of recombinant human Flt3 ectodomain variants in mammalian cells and preliminary crystallographic analysis of Flt3 ligandreceptor complexes. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011;67(3):325-331.
37. Verstraete K, Koch S, Ertugrul S, et al. Efficient production of bioactive recombinant human Flt3 ligand in E. coli. Protein J. 2009;28(2):57-65.
38. Savvides SN, Boone T, Andrew Karplus P. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots. Nat Struct Biol. 2000;7(6):486-491. (Pubitemid 30414471)
39. Cowtan K. Recent developments in classical density modification. Acta Crystallogr D Biol Crystallogr. 2010;66(4):470-478.
40. Huyton T, Zhang JG, Luo CS, et al. An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. Proc Natl Acad Sci U S A. 2007;104(31):12737-12742. (Pubitemid 47255224)
41. Schröder GF, Levitt M, Brunger AT. Super-resolution biomolecular crystallography with low-resolution data. Nature. 2010;464(7292):1218-1222.
42. Blanc E, Roversi P, Vonrhein C, Flensburg C, Lea SM, Bricogne G. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt 1):2210-2221. (Pubitemid 41742773)
43. Harpaz Y, Chothia C. Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains. J Mol Biol. 1994;238(4):528-539. (Pubitemid 24160280)
44. Stroud RM, Wells JA. Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE. 2004;2004(231):re7.
45. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol. 2009;27:29-60.
46. Janin J, Bahadur RP, Chakrabarti P. Protein-protein interaction and quaternary structure. Q Rev Biophys. 2008;41(2):133-180.
47. Sundberg EJ, Mariuzza RA. Molecular recognition in antibody-antigen complexes. Adv Protein Chem. 2002;61:119-160. (Pubitemid 35303456)
48. Graddis TJ, Brasel K, Friend D, et al. Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen. J Biol Chem. 1998;273(28):17626-17633. (Pubitemid 28355100)
49. Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807-811. (Pubitemid 351929632)
50. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood. 1996;88(9):3383-3390. (Pubitemid 26365572)
51. Finger C, Escher C, Schneider D. The single transmembrane domains of human receptor tyrosine kinases encode self-interactions. Sci Signal. 2009;2(89):ra56.
52. Oates J, King G, Dixon AM. Strong oligomerization behavior of PDGFbeta receptor transmembrane domain and its regulation by the juxtamembrane regions. Biochim Biophys Acta. 2010;1798(3):605-615.
53. Schnittger S, Kohl TM, Leopold N, et al. D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. Genes Chromosomes Cancer. 2006;45(4):332-337. (Pubitemid 43346764)
54. Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103(1):267-274. (Pubitemid 38029948)
55. Piloto O, Nguyen B, Huso D, et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006;66(9):4843-4851.
56. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007;450(7172):1001-1009. (Pubitemid 350273630)